Promoter holding
64.27%
CP
Cosmas Pharmacls Limited - Due diligence report
A 360° intelligence report on Cosmas Pharmacls Limited: trust score, financial health, credit view, compliance, directors, growth and distre…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Cosmas Pharmacls Limited — 360° Intelligence Report
Generated from MCA filings & public records52/100
Trust Score
Moderate
Cosmas Pharmacls Limited is assessed as Moderate with a Trust Score of 52/100. Cosmas Pharmacls Limited is an active public limited indian non-government company incorporated in 2010, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.
Report generated on 10 Aug 2026 from the latest processed filings. Cosmas Pharmacls Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
52/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
5/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
60/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Profitable - internal accruals available.
Charges position: 5 open (52.03 cr) · 2 satisfied (1.58 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 2 | 48.0 cr |
| Punjab National Bank | 5 | 48.0 cr |
Compliance Score: 5/100 Caution Indicated
- Company status is Active as per MCA.
- Marked ACTIVE non-compliant (INC-22A).
- Balance sheet slightly behind (Mar 2024).
- Flagged by authority: EPFO, MCA.
- Litigation present in 3 court forum(s).
- 1 auditor resignation(s) filed - latest: GARG SUNIL KUMAR & CO. on 2017-07-03.
- Delayed payments to MSME suppliers disclosed (100 disclosure(s)).
- 2 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 55/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PUNIT JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SANJAY KUMAR JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANU JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TANUJ KUMAR JAIN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KULDIP SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TAPAN KUMAR PAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAM RATTAN GARG | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| PARKASH CHOPRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TILAK RAJ BHARDWAJ | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- MANU JAIN has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: PUNIT JAIN (Managing Director) · SANJAY KUMAR JAIN (Whole-time director) · MANU JAIN (Whole-time director) · TANUJ KUMAR JAIN (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 60 · Distress 75
Growth signals & trust indicators
Profit expanded 1.42 year-on-year.
Net margin improved to 2.1x.
EPFO headcount growing - hiring signal.
Operating for 16+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Compliance score is weak (5/100).
5 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 85.93 Lakh.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence40/100
Caution indicated
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment39/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 5 open charge(s) of 52.03 cr already registered.
- Compliance gaps should be priced into terms.
Investor view60/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
15 Oct 2013
Director ceased
DINESHKUMAR ATTARCHAND VERMA
31 Oct 2012
Director ceased
SIMPAL KUMARI
31 Mar 2012
Securities allotted
1000000.00 Equity Shares - 10.00 cr raised
03 Sep 2011
Charge satisfied
Punjab National Bank
01 Sep 2011
Charge satisfied
Punjab National Bank
03 Jun 2011
Director ceased
MANPREET KAUR
13 Apr 2011
Charge created
Others - 14.27 cr
03 Feb 2011
Charge created
Others - 14.27 cr
28 Sep 2010
Director ceased
KULDIP SINGH
Director ceased
TAPAN KUMAR PAL
Director ceased
RAM RATTAN GARG
Director ceased
PARKASH CHOPRA
Director ceased
TILAK RAJ BHARDWAJ
10
Key Observations
Auto-generated from the data aboveRevenue declined 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Debt-to-equity stands at 38% - leverage worth monitoring.
Net worth is positive.
9 active director(s) / partner(s); review board churn before relying on management continuity.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Dagon Pharmaceuticals | U24231GJ1993PTC019247 | Vadodara, Gujarat, India |
| Metachem Manufacturing Company Private Limited | U51909MH1997PTC112307 | Pune, Maharashtra, India |
| Elikem Pharmaceuticals Private Limited | U24231GJ1992PTC018162 | Kalol, Gujarat, India |
| Den Mark Pharmaceuticals Private Limited | U24304MH2021PTC372188 | Mumbai, Maharashtra, India |
| Gaplgoa | U24231GA1980SGC000412 | Goa, Goa, India |
| Uv Lifecare Limited | U24230HR2021PLC094306 | Panchkula, Haryana, India |
| Nisarga Biotech Private Limited | U24119PN1998PTC114090 | Satara, Maharashtra, India |
| Franklin Laboratories India Pvt Ltd | U24231PB1966PTC002676 | Punjab, Punjab, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Cosmas Pharmacls Limited before audits and certifications: compliance score 5/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Cosmas Pharmacls Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 60/100, margin trends, ownership structure and peer set for Cosmas Pharmacls Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Caution indicated. Trust score 52/100, distress signals and MSME payment-delay disclosures - know whether Cosmas Pharmacls Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Cosmas Pharmacls Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Cosmas Pharmacls Limited an active company?
Cosmas Pharmacls Limited has MCA status “Active” with a compliance score of 5/100 (Caution Indicated).
Is Cosmas Pharmacls Limited financially healthy?
Cosmas Pharmacls Limited has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.
Should I do business with Cosmas Pharmacls Limited?
Its overall Trust Score is 52/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Cosmas Pharmacls Limited?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 9 active director(s) are on record.
Does Cosmas Pharmacls Limited have loans or charges against its assets?
5 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Cosmas Pharmacls Limited up to date with its ROC filings?
Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 5/100 (Caution Indicated).
Is it risky to lend to Cosmas Pharmacls Limited?
Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
